Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReACT: Autologous Bone Marrow Stem Cells for Refractory Angina
NCT01966042Phase 2Completed
- Sponsor
- CellPraxis
- Start
- Jul 2005
- Primary completion
- Nov 2011
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in Angina Pectoris (AP), sponsored by CellPraxis. Primary endpoints: Angina Class Variation (CCSAC) at 12 months, Improvement in Myocardial Perfusion at 12 months and 1 more. Started Jul 2005; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT01966042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966042.